Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Standard

Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study. / Pfeifer, Andreas Klaus; Knigge, Ulrich Peter; Mortensen, Jann; Oturai, Peter; Berthelsen, Anne Kiil; Loft, Annika; Binderup, Tina; Rasmussen, Palle; Elema, Dennis Ringkjøbing; Klausen, Thomas Levin; Holm, Søren; von Benzon, Eric; Højgaard, Liselotte; Kjaer, Andreas.

In: Journal of Nuclear Medicine, Vol. 53, No. 8, 2012, p. 1207-1215.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Harvard

Pfeifer, AK, Knigge, UP, Mortensen, J, Oturai, P, Berthelsen, AK, Loft, A, Binderup, T, Rasmussen, P, Elema, DR, Klausen, TL, Holm, S, von Benzon, E, Højgaard, L & Kjaer, A 2012, 'Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study' Journal of Nuclear Medicine, vol 53, no. 8, pp. 1207-1215., 10.2967/jnumed.111.101469

APA

Pfeifer, A. K., Knigge, U. P., Mortensen, J., Oturai, P., Berthelsen, A. K., Loft, A., ... Kjaer, A. (2012). Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study. Journal of Nuclear Medicine, 53(8), 1207-1215. 10.2967/jnumed.111.101469

CBE

Pfeifer AK, Knigge UP, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema DR, Klausen TL, Holm S, von Benzon E, Højgaard L, Kjaer A. 2012. Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study. Journal of Nuclear Medicine. 53(8):1207-1215. Available from: 10.2967/jnumed.111.101469

MLA

Vancouver

Pfeifer AK, Knigge UP, Mortensen J, Oturai P, Berthelsen AK, Loft A et al. Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study. Journal of Nuclear Medicine. 2012;53(8):1207-1215. Available from: 10.2967/jnumed.111.101469

Author

Pfeifer, Andreas Klaus; Knigge, Ulrich Peter; Mortensen, Jann; Oturai, Peter; Berthelsen, Anne Kiil; Loft, Annika; Binderup, Tina; Rasmussen, Palle; Elema, Dennis Ringkjøbing; Klausen, Thomas Levin; Holm, Søren; von Benzon, Eric; Højgaard, Liselotte; Kjaer, Andreas / Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study.

In: Journal of Nuclear Medicine, Vol. 53, No. 8, 2012, p. 1207-1215.

Publication: Research - peer-reviewJournal article – Annual report year: 2012

Bibtex

@article{185259dfcc594b4ea21fa5f156826f74,
title = "Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study",
keywords = "neuroendocrine tumors, 64Cu-DOTA-Tyr3-octreotate, positron-emission tomography, 111In-DTPA-octreotide, first-in-humans study",
publisher = "Society of Nuclear Medicine",
author = "Pfeifer, {Andreas Klaus} and Knigge, {Ulrich Peter} and Jann Mortensen and Peter Oturai and Berthelsen, {Anne Kiil} and Annika Loft and Tina Binderup and Palle Rasmussen and Elema, {Dennis Ringkjøbing} and Klausen, {Thomas Levin} and Søren Holm and {von Benzon}, Eric and Liselotte Højgaard and Andreas Kjaer",
year = "2012",
doi = "10.2967/jnumed.111.101469",
volume = "53",
number = "8",
pages = "1207--1215",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",

}

RIS

TY - JOUR

T1 - Clinical PET of Neuroendocrine Tumors Using <sup>64</sup>Cu-DOTATATE: First-in-Humans Study

A1 - Pfeifer,Andreas Klaus

A1 - Knigge,Ulrich Peter

A1 - Mortensen,Jann

A1 - Oturai,Peter

A1 - Berthelsen,Anne Kiil

A1 - Loft,Annika

A1 - Binderup,Tina

A1 - Rasmussen,Palle

A1 - Elema,Dennis Ringkjøbing

A1 - Klausen,Thomas Levin

A1 - Holm,Søren

A1 - von Benzon,Eric

A1 - Højgaard,Liselotte

A1 - Kjaer,Andreas

AU - Pfeifer,Andreas Klaus

AU - Knigge,Ulrich Peter

AU - Mortensen,Jann

AU - Oturai,Peter

AU - Berthelsen,Anne Kiil

AU - Loft,Annika

AU - Binderup,Tina

AU - Rasmussen,Palle

AU - Elema,Dennis Ringkjøbing

AU - Klausen,Thomas Levin

AU - Holm,Søren

AU - von Benzon,Eric

AU - Højgaard,Liselotte

AU - Kjaer,Andreas

PB - Society of Nuclear Medicine

PY - 2012

Y1 - 2012

N2 - The use of positron emitter–labeled compounds for somatostatin receptor imaging (SRI) has become attractive because of the prospect of improved spatial resolution, accelerated imaging procedures, and the ability to quantify tissue radioactivity concentrations. This paper provides results from first-in-humans use of 64Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope with intermediate half-life and favorable positron energy (half-life, 12.7 h; maximum positron energy, 0.653 MeV). Methods: In a prospective setup, 14 patients with a history of neuroendocrine tumors underwent both PET/CT with 64Cu-DOTATATE and SPECT/CT with our current routine imaging agent 111In-diethylenetriaminepentaacetic acid–octreotide. After intravenous injection of 193–232 MBq of 64Cu-DOTATATE, whole-body PET scans were acquired at 1 h (n = 14), 3 h (n = 12), and 24 h (n = 5) after administration. Tissue radioactivity concentrations for normal organs and lesions were quantified, and standardized uptake values were calculated for the early (1 h) and delayed (3 h) scans. Using the data for 5 patients, we assessed the radiation dose with OLINDA/EXM software. Furthermore, the clinical performance of 64Cu-DOTATATE with respect to lesion detection was compared with conventional SRI. Results: SRI with 64Cu-DOTATATE produced images of excellent quality and high spatial resolution. Images were characterized by high and stable tumor-to-background ratios over an imaging time window of at least 3 h. Compared with conventional scintigraphy, 64Cu-DOTATATE PET identified additional lesions in 6 of 14 patients (43%). In 5 patients, lesions were localized in organs and organ systems not previously known as metastatic sites, including the early-stage detection of a secondary neuroendocrine tumor in a patient with a known mutation in the multiple endocrine neoplasia type I gene. All major additional findings seen only on PET could be confirmed on the basis of a clinical follow-up interval of 18 mo. Calculated radiation dose estimates yielded an effective dose of 6.3 mSv for an injected activity of 200 MBq of 64Cu-DOTATATE, with the liver being the organ with the highest absorbed radiation dose (0.16 mGy/MBq). Conclusion: This first-in-humans study supports the clinical use of 64Cu-DOTATATE for SRI with excellent imaging quality, reduced radiation burden, and increased lesion detection rate when compared with 111In-diethylenetriaminepentaacetic acid–octreotide.

AB - The use of positron emitter–labeled compounds for somatostatin receptor imaging (SRI) has become attractive because of the prospect of improved spatial resolution, accelerated imaging procedures, and the ability to quantify tissue radioactivity concentrations. This paper provides results from first-in-humans use of 64Cu-DOTATATE, an avidly binding somatostatin receptor ligand linked to a radioisotope with intermediate half-life and favorable positron energy (half-life, 12.7 h; maximum positron energy, 0.653 MeV). Methods: In a prospective setup, 14 patients with a history of neuroendocrine tumors underwent both PET/CT with 64Cu-DOTATATE and SPECT/CT with our current routine imaging agent 111In-diethylenetriaminepentaacetic acid–octreotide. After intravenous injection of 193–232 MBq of 64Cu-DOTATATE, whole-body PET scans were acquired at 1 h (n = 14), 3 h (n = 12), and 24 h (n = 5) after administration. Tissue radioactivity concentrations for normal organs and lesions were quantified, and standardized uptake values were calculated for the early (1 h) and delayed (3 h) scans. Using the data for 5 patients, we assessed the radiation dose with OLINDA/EXM software. Furthermore, the clinical performance of 64Cu-DOTATATE with respect to lesion detection was compared with conventional SRI. Results: SRI with 64Cu-DOTATATE produced images of excellent quality and high spatial resolution. Images were characterized by high and stable tumor-to-background ratios over an imaging time window of at least 3 h. Compared with conventional scintigraphy, 64Cu-DOTATATE PET identified additional lesions in 6 of 14 patients (43%). In 5 patients, lesions were localized in organs and organ systems not previously known as metastatic sites, including the early-stage detection of a secondary neuroendocrine tumor in a patient with a known mutation in the multiple endocrine neoplasia type I gene. All major additional findings seen only on PET could be confirmed on the basis of a clinical follow-up interval of 18 mo. Calculated radiation dose estimates yielded an effective dose of 6.3 mSv for an injected activity of 200 MBq of 64Cu-DOTATATE, with the liver being the organ with the highest absorbed radiation dose (0.16 mGy/MBq). Conclusion: This first-in-humans study supports the clinical use of 64Cu-DOTATATE for SRI with excellent imaging quality, reduced radiation burden, and increased lesion detection rate when compared with 111In-diethylenetriaminepentaacetic acid–octreotide.

KW - neuroendocrine tumors

KW - 64Cu-DOTA-Tyr3-octreotate

KW - positron-emission tomography

KW - 111In-DTPA-octreotide

KW - first-in-humans study

U2 - 10.2967/jnumed.111.101469

DO - 10.2967/jnumed.111.101469

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

VL - 53

SP - 1207

EP - 1215

ER -